Top

Published in:

01-03-2016 | Gynecologic Endocrinology and Reproductive Medicine

Effect of colchicine on polycystic ovary syndrome: an experimental study

Authors: Ilay Ozturk Gozukara, Neslihan Pınar, Oğuzhan Ozcan, Tumay Ozgur, Recep Dokuyucu, Raziye Keskin Kurt, Suna Kabil Kucur, Ayşe Nur Aksoy

Published in: Archives of Gynecology and Obstetrics | Issue 3/2016

Abstract

Purpose

To investigate whether there is any therapeutic effect of colchicine on a rat model of polycystic ovary syndrome (PCOS).

Methods

Twenty-two Wistar-Albino rats were randomly assigned into four with 8 rats in each group: control group; PCOS only group; PCOS-metformin group and PCOS-colchicine group. PCOS was induced by gavage with letrozole once daily at the concentration of 1 mg/kg orally with 21 consecutive days. After PCOS model assessment, PCOS-metformin group was received metformin orally with 500 mg/kg and PCOS-colchicine group was received colchicine orally with 1 mg/kg for the 35 day. Histopathology of ovaries, circulating estrone (E₁), estradiol (E₂), total testosterone, androstenedione and c-reactive protein (CRP) levels were evaluated. Results: cystic and atretic follicle number was significantly decreased, but CRP and hormone parameters were not significantly changed with colchicine treatment.

Conclusion

Colchicine has provided histopathological improvement compared with metformin in PCOS rat model.

Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352:1223–1236CrossRefPubMed

Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146CrossRefPubMed

Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453–2455CrossRefPubMed

Sabuncu T, Vural H, Harma M, Harma M (2001) Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 34:407–413CrossRefPubMed

Sam S, Dunaif A (2003) Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metabo 14:365–370CrossRef

Gonzalez F, Rote NS, Minium J, Kirwan JP (2006) Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 91:1508–1512CrossRefPubMed

Ergenoglu M, Yildirim N, Yildirim AG, Yeniel O, Erbas O, Yavasoglu A et al (2015) Effects of resveratrol on ovarian morphology, plasma anti-mullerian hormone, IGF-1 levels, and oxidative stress parameters in a rat model of polycystic ovary syndrome. Reprod Sci 22(8):942–947CrossRefPubMed

Sayin NC, Gucer F, Balkanli-Kaplan P, Yuce MA, Ciftci S, Kucuk M et al (2003) Elevated serum TNF-alpha levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 48:165–170PubMed

Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L et al (2005) The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 90:2–5CrossRefPubMed

10.

Ibanez L, Jaramillo AM, Ferrer A, de Zegher F (2005) High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum Reprod 20:2457–2462CrossRefPubMed

11.

Schlesinger N, Schumacher R, Catton M, Maxwell L (2006) Colchicine for acute gout. Cochrane Database Syst Rev 8:CD006190

12.

Niel E, Scherrmann JM (2006) Colchicine today. Join, Bone Spine 73:672–678CrossRef

13.

Molad Y (2002) Update on colchicine and its mechanism of action. Curr Rheumatol Rep 4:252–256CrossRefPubMed

14.

Roberge CJ, Gaudry M, de Medicis R, Lussier A, Poubelle PE, Naccache PH (1993) Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Investig 92:1722–1729PubMedCentralCrossRefPubMed

15.

Li Z, Davis GS, Mohr C, Nain M, Gemsa D (1996) Inhibition of LPS-induced tumor necrosis factor-alpha production by colchicine and other microtubule disrupting drugs. Immunobiology 195:624–639CrossRefPubMed

16.

Ding AH, Porteu F, Sanchez E, Nathan CF (1990) Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents. J Exp Med 171:715–727CrossRefPubMed

17.

Marcondes FK, Bianchi FJ, Tanno AP (2002) Determination of the estrous cycle phases of rats: some helpful considerations. Braz J Biol 62:609–614CrossRefPubMed

18.

Kafali H, Iriadam M, Ozardali I, Demir N (2004) Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res 35:103–108CrossRefPubMed

19.

Lee FY, Lu HI, Zhen YY, Leu S, Chen YL, Tsai TH et al (2013) Benefit of combined therapy with nicorandil and colchicine in preventing monocrotaline-induced rat pulmonary arterial hypertension. Eur J Pharm Sci 50:372–384CrossRefPubMed

20.

Elia E, Sander V, Luchetti CG, Solano ME, Di Girolamo G, Gonzalez C et al (2006) The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Mol Hum Reprod 12:475–481CrossRefPubMed

21.

Atis A, Aydin Y, Ciftci F, Sakiz D, Arslan A, Toklu AS et al (2012) Hyberbaric oxygen increases atresia in normal & steroid induced PCO rat ovaries. Reprod Biol Endocrinol 10:11PubMedCentralCrossRefPubMed

22.

Luque-Ramirez M, Escobar-Morreale HF (2010) Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. Horm Metab Res 42:815–820CrossRefPubMed

23.

Diamanti-Kandarakis E, Paterakis T, Kandarakis HA (2006) Indices of low-grade inflammation in polycystic ovary syndrome. Ann N Y Acad Sci 1092:175–186CrossRefPubMed

24.

Sirmans SM, Pate KA (2013) Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 6:1–13PubMedCentralCrossRefPubMed

25.

DeVane GW, Czekala NM, Judd HL, Yen SS (1975) Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 121:496–500PubMed

26.

Gonzalez F, Rote NS, Minium J, Kirwan JP (2006) Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91:336–340CrossRefPubMed

27.

Gonzalez F, Rote NS, Minium J, Kirwan JP (2009) Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metab, Clin Exp 58:954–962CrossRef

28.

Ojeda-Ojeda M, Murri M, Insenser M, Escobar-Morreale HF (2013) Mediators of low-grade chronic inflammation in polycystic ovary syndrome (PCOS). Curr Pharm Des 19:5775–5791CrossRefPubMed

29.

Gozdemir E, Kaygusuz I, Kafali H (2013) Is hepcidin a new cardiovascular risk marker in polycystic ovary syndrome? Gynecol Obstet Invest 75:196–202CrossRefPubMed

30.

Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F (2011) Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 95(1048–58):e1–e2

31.

Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T et al (2004) The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150:525–532CrossRefPubMed

32.

Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS (2003) Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:4649–4654CrossRefPubMed

33.

Phelps P (2008) Polymorphonuclear leukocyte motility in vitro: IV. Colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystals. Arthritis Rheum 58:S25–S33CrossRefPubMed

34.

Das UN (1993) Colchicine in diabetes mellitus. J Assoc Phys India 41:213

35.

Huang C, Cen C, Wang C, Zhan H, Ding X (2014) Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis 13:67PubMedCentralCrossRefPubMed

36.

Kurt RK, Dogan AC, Dogan M, Albayrak A, Kurt SN, Eren F et al (2014) Protective effect of colchicine on ovarian ischemia-reperfusion injury: an experimental study. Reprod Sci 22(5):545–550 CrossRefPubMed

37.

Kurt RK, Pinar N, Karateke A, Okyay AG, Silfeler DB, Albayrak A et al (2015) Protective effects of colchicine in an experimental rat endometriosis model: histopathological evaluation and assessment of TNF-alpha levels. Reprod Sci 22:258–263CrossRefPubMed

Title: Effect of colchicine on polycystic ovary syndrome: an experimental study
Authors: Ilay Ozturk Gozukara
Neslihan Pınar
Oğuzhan Ozcan
Tumay Ozgur
Recep Dokuyucu
Raziye Keskin Kurt
Suna Kabil Kucur
Ayşe Nur Aksoy
Publication date: 01-03-2016
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 3/2016
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-015-3933-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of colchicine on polycystic ovary syndrome: an experimental study

Abstract

Purpose

Methods

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2016

Endometrial polyps: when to resect?

Erratum to: Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study

The influence of AMH on IVF success

Clinical characteristics of adnexal torsion in premenarchal patients

Laparoscopic ovariectomy by single-port access for ovarian cryopreservation

Induction of labor in breech presentations at term: a retrospective observational study